Pettersson Helen M, Karlsson Jenny, Pietras Alexander, Øra Ingrid, Påhlman Sven
Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden.
J Bioenerg Biomembr. 2007 Feb;39(1):35-41. doi: 10.1007/s10863-006-9058-6.
The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells.
大多数侵袭性儿童肿瘤神经母细胞瘤，按照目前的治疗方案无法治愈，这是儿科肿瘤学面临的一项重大挑战。在首轮化疗、手术和放疗之后（多数情况下会导致肿瘤消退），这些侵袭性神经母细胞瘤会复发，并常常产生耐药性。由于约50%的神经母细胞瘤患儿患的是侵袭性类型，因此迫切需要新的治疗策略。三氧化二砷有能力在体外和体内杀死多药耐药神经母细胞瘤细胞，目前该药物正在进行临床试验评估。在本报告中，我们讨论了三氧化二砷用于癌症治疗的背景，以及目前已知的三氧化二砷杀死人类神经母细胞瘤细胞的机制。
